EU regulators have published a much-awaited recommendation paper offering their harmonized perspective on the use of decentralized elements in clinical trials undertaken in the EU/European Economic Area.
The recommendation paper, published on 14 December, is a joint initiative of the European Medicines Agency, the European Commission and the EU Heads of Medicines Agencies (HMA)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?